S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE

• A. Hernández-Sánchez,
• Á. Villaverde-Ramiro,
• J. Martínez Elicegui,
• T. González,
• A. Benner,
• E. Sträng,
• G. Castellani,
• C. A. Heckman,
• J. Versluis,
• M. Abáigar,
• M. Sobas,
• R. Azibeiro,
• L. Tur,
• P. J. Valk,
• K. H. Metzeler,
• R. Ayala,
• D. Dall’Olio,
• J. Tettero,
• J. Martínez-López,
• H. Dombret,
• M. Pratcorona,
• F. Damm,
• K. I. Mills,
• J. Mayer,
• C. Thiede,
• M. T. Voso,
• G. F. Sanz,
• F. Calado,
• K. Döhner,
• V. I. Gaidzik,
• M. Heuser,
• T. Haferlach,
• A. T. Turki,
• D. Reinhardt,
• R. Villoria Medina,
• M. van Speybroeck,
• R. Schulze-Rath,
• M. Barbus,
• J. E. Butler,
• J. M. Hernández Rivas,
• B. J. Huntly,
• G. J. Ossenkoppele,
• H. Döhner,
• L. Bullinger

Affiliations

A. Hernández-Sánchez

1 Hospital Universitario de Salamanca

Á. Villaverde-Ramiro

2 Instituto de Investigación Biomédica de Salamanca (IBSAL)

J. Martínez Elicegui

2 Instituto de Investigación Biomédica de Salamanca (IBSAL)

T. González

2 Instituto de Investigación Biomédica de Salamanca (IBSAL)

A. Benner

4 German Cancer Research Center (DKFZ), Heidelberg

E. Sträng

5 Charité Universitätsmedizin Berlin, Berlin, Germany

G. Castellani

6 University of Bologna, Bologna, Italy

C. A. Heckman

7 University of Helsinki

J. Versluis

9 Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands

M. Abáigar

2 Instituto de Investigación Biomédica de Salamanca (IBSAL)

M. Sobas

10 Wroclaw Medical University, Wroclaw, Poland

R. Azibeiro

1 Hospital Universitario de Salamanca

L. Tur

11 GMV Innovating Solutions, Valencia, Spain

P. J. Valk

9 Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands

K. H. Metzeler

12 University of Munich, Munich, Germany

R. Ayala

13 Hospital Universitario

D. Dall’Olio

6 University of Bologna, Bologna, Italy

J. Tettero

14 Amsterdam University Medical Center, Amsterdam, Netherlands

J. Martínez-López

13 Hospital Universitario

H. Dombret

15 EA3518 Leukemia Translational Laboratory, Paris, France

M. Pratcorona

16 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

F. Damm

5 Charité Universitätsmedizin Berlin, Berlin, Germany

K. I. Mills

17 Queens University Belfast, Belfast, United Kingdom

J. Mayer

18 University Hospital Brnoand Masaryk University, Brno, Czechia

C. Thiede

19 University of Technics Dresden Medical Dept., Dresden, Germany

M. T. Voso

20 University of Rome “Cattolica S. Cuore”, Rome, Italy

G. F. Sanz

20 University of Rome “Cattolica S. Cuore”, Rome, Italy

F. Calado

23 Novartis, Oncology Region Europe, Basel, Switzerland

K. Döhner

24 University Hospital of Ulm

V. I. Gaidzik

25 Ulm University Hospital, Ulm

M. Heuser

26 Hannover Medical School, Hannover

T. Haferlach

27 MLL Munich Leukemia Laboratory, Munich

A. T. Turki

27 MLL Munich Leukemia Laboratory, Munich

D. Reinhardt

28 Essen University Hospital

R. Villoria Medina

11 GMV Innovating Solutions, Valencia, Spain

M. van Speybroeck

30 Janssen Pharmaceutica N.V., Beerse, Belgium

R. Schulze-Rath

31 Bayer Pharma AG, Berlin

M. Barbus

32 AbbVie Germany GmbH & Co. KG, Wiesbaden

J. E. Butler

33 Bayer AG, Berlin, Germany

J. M. Hernández Rivas

1 Hospital Universitario de Salamanca

B. J. Huntly

34 Wellcome - MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom

G. J. Ossenkoppele

12 de Octubre, Madrid, Spain

H. Döhner

24 University Hospital of Ulm

L. Bullinger

5 Charité Universitätsmedizin Berlin, Berlin, Germany